Audio Conference on May 21st: 2:00 - 3:30 Eastern Time
Congress is considering various policy options that may significantly increase federal funding for comparative effectiveness research (CER). This could have significant ramifications for laboratory testing.
CER is an evidenced-based research tool, which compares different health services or treatment options for the same condition, so that health care professionals can personalize patient care.
The good news is that an increase in CER studies may provide laboratories with important information for assessing tests and improving test selection. In addition, these studies may provide needed data for new guideline development. However, there are also potential pitfalls associated with CE, such as how payers use the data. Will they use it to restrict coverage or reduce payments for certain tests? If insurers choose this route, what will it mean for clinical laboratories and test developers?
Join us for a 90-minute, information-packed program and learn the answers to these questions and more. Also, as a bonus, you'll get the latest on congressional efforts in this area.
This is a must attend event for clinical laboratories and manufacturers!